Home   About this service   Get the news  
+32 2 743 34 03

 Belgium  Other Countries
Page : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - ...
 
UCB [BE0003739530/UCB]   
[24/01/2022]

UCB : UCB Media Room: BIMZELX® (bimekizumab) Approved in Japan

https://mb.cision.com/Public/18595/logo/86a99b25f755738d_org.jpg BIMZELX^=C2=AE bimekizumab Approved in Japan for the Treatment of Plaq= ue Psoriasis, Generalized Pustular Psoriasis and Psoriatic Erythroderma =C2=B7 The third approval for bimekizumab worldwide reinforces UCB=E2=80=99= s commitment to bring new treatment options to the global dermatology commu= nity =C2=B7 Approval is... See more
 
UCB [BE0003739530/UCB]   
[21/01/2022]

UCB : UCB Media Room: Disposals of own shares

https://mb.cision.com/Public/18595/logo/86a99b25f755738d_org.jpg Disposals of own shares Brussels Belgium, 21 January 2022 =E2=80=93 20:00 CET =E2=80=93 regulat= ed information Disposal of own shares In accordance with article 8:6 of the Royal Decree executing the Belgian Co= de of Companies and Associations, UCB announces that, following exercises o= f stock options by members... See more
 
UCB [BE0003739530/UCB]   
[21/01/2022]

UCB : UCB Media Room: Top-Line Results for BIMZELX®▼(bimekizumab) in Second Phase 3 Psoriatic Arthritis Study

https://mb.cision.com/Public/18595/logo/86a99b25f755738d_org.jpg Positive TopLine Results for BIMZELX^=C2=AE=E2=96=BCbimekizumab in Se= cond Phase 3 Psoriatic Arthritis Study =C2=B7 The BE COMPLETE study evaluated bimekizumab in adults with active ps= oriatic arthritis who were inadequate responders or intolerant to antiTNF = treatment =C2=B7 BE COMPLETE is the second positive Phase... See more
 
ECONOCOM GROUP [BE0974313455/ECONB]   
[20/01/2022]

ECONOCOM GROUP : LE GROUPE ECONOCOM RENFORCE SA GOUVERNANCE

Le Groupe Econocom renforce sa gouvernance Nominations de Monsieur Laurent Roudil au poste d'Administrateur Délégué – CEO et de Monsieur Angel Benguigui au poste Directeur Général Délégué Après une période d'assainissement et de consolidation...